ursodeoxycholic acid PO tablet - Daewoong Pharmaceutical
Alternative Names: DWC-202108; DWJ-1439Latest Information Update: 28 Aug 2023
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea (PO)
- 30 Jan 2023 Daewoong Pharmaceutical completes the Phase I trial for Unknown indication in South Korea (NCT05832697)
- 27 Jan 2022 Daewoong Pharmaceutical initiates enrolment in the Phase I trial for Unknown indication in South Korea (NCT05832697)